Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Antipsychotic medications in people with dementia should be avoided or limited to treatment courses of fewer than 3-4 months. It is unknown whether discontinuation of long-term antipsychotic medications in this population can improve clinical outcomes. This study evaluated clinical outcomes associated with discontinuation of long-term antipsychotic medication use compared with continued use among individuals with dementia residing in nursing homes. Methods This cohort study used Medicare claims data (2013-2022) linked to Minimum Data Set clinical assessment data. The study population included nursing home residents aged ≥ 65 with dementia who had used antipsychotic medications for more than 90 days. Individuals who discontinued antipsychotic medications (gap ≥ 60 days) were matched to continuers using incidence density sampling based on time since first prescription of antipsychotic medications. Propensity score matching was applied to adjust for 86 covariates. Study outcomes included all-cause hospitalization, specific rehospitalization reasons, and all-cause mortality. Hazard ratios (HRs) were estimated using Cox proportional hazards model, and rate differences (RDs) per 1,000 person-years were estimated using generalized linear models. Results Two thousand one hundred eleven propensity score-matched pairs were included and followed for a median of 298 days. Antipsychotic medication discontinuation versus continuation was associated with lower risk of all-cause hospitalization (HR [95% CI]: 0.83 [0.72, 0.96]; RD [95% CI]: -55.85 [-97.82, -13.88]) and hospitalization for pneumonia (HR: 0.51 [0.29, 0.90]; RD: -12.85 [-23.26, -2.44]) or urinary tract infections (HR: 0.47 [0.26, 0.83]; RD: -14.22 [-24.62, -3.83]); non-significantly lower risks of hospitalization for falls (HR: 0.88 [0.70, 1.11]; RD: -13.19 [-37.78, 11.41]), delirium (HR: 0.76 [0.57, 1.02]; RD: -19.26 [-39.18, 0.66]), stroke (HR: 0.95 [0.42, 2.16]; RD: -0.31 [-7.06, 6.44]), and all-cause mortality (HR: 0.89 [0.79, 1.02]; RD: -38.23 [-81.01, 4.54]). Subgroup analyses showed the greatest reduction in hospitalization risk was among individuals with moderate-to-severe dementia (HR: 0.78 [95% CI: 0.65, 0.93]; RD: -96.76 [-163.75, -29.77]). Conclusions Among nursing home residents with dementia, discontinuing long-term antipsychotic medication use was associated with lower risks of hospitalization, pneumonia, and urinary tract infections, suggesting clinical benefits in this population.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 4,222 participants. This cohort study found that discontinuing long-term antipsychotics in nursing home residents with dementia was associated with lower risk of all-cause hospitalization compared with continued use. Reported effect size: All-cause hospitalisation HR 0.83 (95% CI 0.72-0.96); pneumonia hospitalisation HR 0.51 (0.29-0.90).

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yang, C. T., Wilkins, J. M., Kesselheim, A. S., Kim, D. H., & Lin, K. J. (2026). Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-026-02134-0

Vancouver

Yang CT, Wilkins JM, Kesselheim AS, Kim DH, Lin KJ. Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study. Alzheimer's Research & Therapy. 2026. doi:10.1186/s13195-026-02134-0. PMID: 42410659.

BibTeX

@article{yang2026-42410659,
  author  = {Yang, C. T. and Wilkins, J. M. and Kesselheim, A. S. and Kim, D. H. and Lin, K. J.},
  title   = {{Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study}},
  journal = {Alzheimer's Research \& Therapy},
  year    = {2026},
  doi     = {10.1186/s13195-026-02134-0},
  pmid    = {42410659},
  url     = {https://doi.org/10.1186/s13195-026-02134-0}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This cohort study found that discontinuing long-term antipsychotics in nursing home residents with dementia was associated with lower risk of all-cause hospitalization compared with continued use. It suggests that stopping these medications may improve some clinical outcomes.

Study details

Limitations

Observational; residents who stopped may have been improving already; matching on 86 covariates cannot remove all confounding; no data on behavioural symptoms after discontinuation.

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 51 of the 98 points it could be judged on, which is 52 of 100. Total 52 of 100.51 of the 98 points we could judge = 52 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 51 of the 98 points we could judge it on, which is 52 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer's Research & Therapy)
Journal's citation record 1 / 4 Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 4,222 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Kueiyu Joshua Lin: h-index 28 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42410659)
Free to read — / 2 Access not recorded — left out of this score
Points 51 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 98 points we could judge it on is 52 out of 100.
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “nursing”

995 studies in the library carry the topic tag “nursing”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 995 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →